|Astrazeneca plc, of Cambridge, U.K.||Imfinzi (durvalumab)||Monoclonal antibody targeting PD-L1||Non-small-cell lung cancer and bladder cancer||FDA granted priority review for a new 4-week, fixed-dose regimen|
|Emmaus Life Sciences Inc., of Torrance, Calif.||Endari||L-glutamine oral powder||Sickle cell disease||Submitted an MAA to the Saudi Food and Drug Authority|
|Immatics NV, of Tuebingen, Germany||IMA-203||Targets peptides derived from preferentially expressed antigen in melanoma||Solid tumors expressing preferentially expressed antigen in melanoma||Germany's Paul-Ehrlich-Institute approved the CTA for a phase I study|
|Kimera Labs Inc., of Miramar, Fla.||Xoglo||Isolated placental mesenchymal stem cell-based exosomes||Acute respiratory distress syndrome secondary to COVID-19 infection||Filed an IND application with the FDA|
|Krystal Biotech Inc., of Pittsburgh, Pa.||KB-407||Inhaled, repeat-dose gene therapy product||Cystic fibrosis||Granted orphan drug designation by the FDA|
For more information about individual companies and/or products, see Cortellis.